High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.
about
Crystal Structures of HIV-1 Reverse Transcriptase with Picomolar Inhibitors Reveal Key Interactions for Drug DesignStructure-Based Evaluation of C5 Derivatives in the Catechol Diether Series Targeting HIV-1 Reverse TranscriptaseStructural Maturation of HIV-1 Reverse Transcriptase-A Metamorphic Solution to Genomic InstabilityHIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide SubstrateConservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patientsA very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAARTImpact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.Co-lethality studied as an asset against viral drug escape: the HIV protease case.Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitorsReconstructing the timing and dispersion routes of HIV-1 subtype B epidemics in the Caribbean and Central America: a phylogenetic storyStructure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.Reverse transcriptase substitution at codons 208 and 228 among treatment-experienced HIV-1 subtype-C-infected Indian patients is strongly associated with thymidine analogue mutationsCharacterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.Short communication: Nucleotide variation and positively selected sites in HIV type 1 reverse transcriptase among heterosexual transmission pairsDetection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy.Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations.Analysis of selection pressure and mutational pattern of HIV type 1 reverse transcriptase region among treated and nontreated patients.Structure-enhanced methods in the development of non-nucleoside inhibitors targeting HIV reverse transcriptase variants.Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection.Novel Mutations L228I and Y232H Cause Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Combinational PatternIdentification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.Solution structural dynamics of HIV-1 reverse transcriptase heterodimer.Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistanceReliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels.Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.Identification of novel bifunctional HIV-1 reverse transcriptase inhibitors.
P2860
Q27675166-61A475ED-C963-4939-9D77-59CF13BBDC7AQ27680709-A65569C2-A205-4E77-9AB7-70AF5B9EC1C6Q28074527-7A2E0D1E-300B-404A-AB03-8309522CC4F4Q28250395-DF033B29-632F-4EEA-8A81-31EA13F33F48Q28472255-D65ED9C3-EDDC-46E6-917D-42E7641CD549Q28542548-000A17BD-31CA-4331-B825-7E609AB755AAQ33624190-28E891D8-8024-450C-97B6-1B5F7718FF97Q33968760-22368C3E-9957-4793-B078-3A94F59EF546Q34717615-9AAA7D42-6624-4A26-BBF8-D7B45C73CD2DQ34853449-9DE82D9D-D1E6-4A12-990A-F8FD6AB39B19Q35228851-D1EA49BA-65B7-4329-AE95-72BB1A796ABBQ35676056-A59BB205-A23C-4D15-BD0F-CB401BD22DA1Q36099251-B888F1AF-53C8-4FC4-857D-E278047E02F8Q36433533-EDE68A40-8179-4824-A664-EE3DFA6C7D13Q36494284-06C48308-3E90-4599-8D45-68959CDAC8D8Q37256719-74DEAD29-2E43-4FFE-B170-249ADEF8F95EQ37409842-A9243F55-EE7E-4E8E-873B-4F22A5BDBE9BQ37550353-263F6578-61B9-4164-8005-A41343901ECEQ38620336-EFDB5BCE-E683-41D3-A2A3-5BCA01FAC4C1Q38975330-2979281C-447A-47B3-9F06-D0630B5C17C3Q39627546-9BE29F1D-8BD4-45EE-A25E-8326610D19E6Q40013658-CB029485-CFE9-491F-B4B9-BB50B15B6F9DQ41775388-E427BB4A-901A-4259-9902-E37B7C2B4289Q41868619-C67A3CF0-CAE0-4D2E-A1D2-9006165F9B58Q42243024-3BF87651-30DA-4AF4-ABAB-06A85E144698Q42917410-925E237D-EADC-44D7-80A0-632B663F11F7Q47613826-016B4129-1A3B-42E2-A4EA-A1CF451CE9A3
P2860
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
High sequence conservation of ...... nuous appearance of mutations.
@ast
High sequence conservation of ...... nuous appearance of mutations.
@en
type
label
High sequence conservation of ...... nuous appearance of mutations.
@ast
High sequence conservation of ...... nuous appearance of mutations.
@en
prefLabel
High sequence conservation of ...... nuous appearance of mutations.
@ast
High sequence conservation of ...... nuous appearance of mutations.
@en
P2093
P2860
P50
P1433
P1476
High sequence conservation of ...... nuous appearance of mutations.
@en
P2093
Carlo-Federico Perno
Fátima Rodríguez-Barrios
Roberta d'Arrigo
Valentina Svicher
P2860
P304
10718-10729
P356
10.1128/JVI.79.16.10718-10729.2005
P407
P50
P577
2005-08-01T00:00:00Z